Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Literature
1.
Mizumachi T, Kano S, Sakashita T et al (2012) Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Int J Clin Oncol. [Epub ahead of print]
2.
3.
Ang KK, Sturgis EM (2012) Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol 22:128–142PubMedCrossRef
4.
Broglie MA, Soltermann A, Haile SR et al (2013) Quality of life of oropharyngeal cancer patients with respect to treatment strategy and p16-positivity. Laryngoscope 123:164–170PubMedCrossRef
5.
Lassen P, Eriksen JG, Krogdahl A et al (2011) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 100:49–55PubMedCrossRef
6.
Quon H, Forastiere AA (2013) Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? J Clin Oncol 31:520–522PubMedCrossRef
7.
Langendijk JA, Psyrri A (2010) The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: implications for treatment strategies and future clinical studies. Ann Oncol 21:1931–1934PubMedCrossRef
Metadata
Title
Do patients with head and neck human papillomavirus-related carcinoma need a different treatment approach?
Authors
Jon Cacicedo Fernandez de Bobadilla
Pedro Bilbao
Publication date
01-08-2014
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2014
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-013-0600-3

Other articles of this Issue 4/2014

International Journal of Clinical Oncology 4/2014 Go to the issue

Review Article

Recent advances in radiation oncology: intensity-modulated radiotherapy, a clinical perspective

Original Article

Preoperative prognostic factors for biochemical recurrence after robot-assisted radical prostatectomy in Japan

Original Article

Effect of port-care frequency on venous port catheter-related complications in cancer patients

Original Article

Remnant liver volume-based predictors of postoperative liver dysfunction after hepatectomy: analysis of 625 consecutive patients from a single institution

Letter to the Editor

Postdural puncture headache: a neglected complication after lumbar puncture and intrathecal chemotherapy in children with acute lymphoblastic leukemia

Original Article

The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits